tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Thiogenesis Advances MELAS Treatment Trial

Thiogenesis Advances MELAS Treatment Trial

Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Thiogenesis Therapeutics, Corp. has announced the European Medicines Agency’s acceptance of its Clinical Trial Application for TTI-0102, aimed at treating MELAS, a rare, inherited mitochondrial disorder with no current approved drugs. This marks a significant milestone as the company prepares to launch a Phase 2 trial in the second quarter of 2024, which will assess the efficacy and safety of TTI-0102 in a double-blind study involving 12 patients across France and the Netherlands. The excitement within Thiogenesis is palpable, as TTI-0102, patented in 2021, shows promise as a treatment for those afflicted by MELAS following a successful preliminary study.

For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1